Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Microvasc Res. 2023 Nov;150:104572. doi: 10.1016/j.mvr.2023.104572. Epub 2023 Jun 21.
Pathological cardiac hypertrophy is an adaptive reaction in response to pressure or volume overload. Autophagy is critical for damage caused by pathological cardiac hypertrophy. Vacuole membrane protein 1 (VMP1) is an endoplasmic reticulum (ER) transmembrane protein that is effective in activating autophagy. However, the role of VMP1 in pathological cardiac hypertrophy and its underlying mechanisms remain elusive. This study was designed to explore the potential mechanisms of VMP1 on pressure overload-induced pathological cardiac hypertrophy. In this work, abdominal aorta constriction (AAC) surgery was used to induce pathological cardiac hypertrophy in male C57BL/6 mice. H9C2 cardiomyocytes were treated with phenylephrine stimulation (PE) to induce the hypertrophic response. The in vivo results revealed that mice with AAC surgery caused pathological cardiac hypertrophy as evidenced by improved cardiac function according to multiple echocardiographic parameters. Moreover, elevated VMP1 expression was also observed in mice after AAC surgery. VMP1 knockdown aggravated changes in cardiac structure, cardiac dysfunction, and fibrosis. Meanwhile, VMP1 knockdown suppressed autophagy and endoplasmic reticulum calcium ATPase (SERCA) activity in heart tissues. H9C2 cardiomyocytes with VMP1 overexpression were used to investigate the specific mechanism of VMP1 in pathological cardiac hypertrophy, and VMP1 overexpression increased autophagic flux by upregulating SERCA activity. In conclusion, these findings revealed that VMP1 protected against pressure overload-induced pathological cardiac hypertrophy by inducing SERCA-regulated autophagic flux. Our results provide valuable insights regarding the pathophysiology of pathological cardiac hypertrophy and clues to a novel target for the treatment of pathological cardiac hypertrophy.
病理性心肌肥厚是一种对压力或容量超负荷的适应性反应。自噬对于病理性心肌肥厚引起的损伤至关重要。液泡膜蛋白 1(VMP1)是一种内质网(ER)跨膜蛋白,可有效激活自噬。然而,VMP1 在病理性心肌肥厚中的作用及其潜在机制仍不清楚。本研究旨在探讨 VMP1 对压力超负荷诱导的病理性心肌肥厚的潜在机制。在这项工作中,采用腹主动脉缩窄(AAC)手术诱导雄性 C57BL/6 小鼠发生病理性心肌肥厚。用苯肾上腺素刺激(PE)处理 H9C2 心肌细胞诱导肥大反应。体内结果表明,AAC 手术后的小鼠心脏功能得到改善,多项超声心动图参数表明发生了病理性心肌肥厚。此外,AAC 手术后小鼠的 VMP1 表达也升高。VMP1 敲低加重了心脏结构变化、心功能障碍和纤维化。同时,VMP1 敲低抑制了心脏组织中的自噬和内质网钙 ATP 酶(SERCA)活性。使用过表达 VMP1 的 H9C2 心肌细胞来研究 VMP1 在病理性心肌肥厚中的具体机制,结果显示 VMP1 通过上调 SERCA 活性增加自噬通量。综上所述,这些发现表明,VMP1 通过诱导 SERCA 调节的自噬通量来保护心脏免受压力超负荷诱导的病理性心肌肥厚。我们的研究结果为病理性心肌肥厚的病理生理学提供了有价值的见解,并为病理性心肌肥厚的治疗提供了新的靶点。